Category

• Pipeline2

Organizations

• Bausch + Lomb66
• Eyes On Eyecare47
• Alcon, Inc.44
• American Optometric Association35
• Harrow29
• Glaukos26
• Regeneron23
• Topcon Healthcare23
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• Clinical Trials2
• Retina2
• AMD1
• Stargardt Disease1
• Geographic Atrophy1
• Visual Acuity1

• Organizations: Belite Bio✕

Clear all

Pipeline

Belite Bio reports phase 3 topline data on oral tinlarebant for Stargardt disease

DRAGON study is evaluating the once-daily tablet for reducing lesion growth among adolescent patients over a 24-month period.

Pipeline

Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant

Also under clinical development for Stargardt disease, the once-daily tablet is under evaluation for its efficacy in slowing atrophic lesion growth.